ClinicalTrials.gg
TerminatedNCT04062266Updated Oct 16, 2026

AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission

A Phase 2 interventional study of Azacitidine and Venetoclax in Acute Myeloid Leukemia in Remission, FLT3 Gene Mutation and Hematologic and Lymphocytic Disorder, sponsored by M.D. Anderson Cancer Center. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Primary conditionLeukemia, Myeloid, AcuteRegistry: Hematologic DiseasesReclassifiedWhy we changed it
Registry
Hematologic Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Leukemia, Myeloid, Acute
Why
  1. The study's listed conditions name Leukemia, Myeloid, Acute, a narrower term within Hematologic Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by M.D. Anderson Cancer Center · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
\<75% participation
Updated Oct 16, 2026Now TerminatedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 214 studies testing azacitidine in Leukemia, Myeloid, Acute — 72 open to participants now, 91 under way, 11 of them phase 3. Azacitidine · Leukemia, Myeloid, Acute.

Enrollment
134th of 211
36 · median 50
Started
2019
with 8 others
Phase 2
105 of 214
40 open now
Registered
99th of 214
by date
Lead sponsor
19 of 214
M.D. Anderson Cancer Center

Among the 214 studies testing azacitidine in Leukemia, Myeloid, Acute, this one is the 134th largest by enrollment of the 211 interventional ones that give a count, is one of 9 that started in 2019, is one of 105 in phase 2, and was the 99th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

72 of the 214 studies testing azacitidine in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

67 more — sign in →

By country, each count listing its studies:

All 72 open studies →

About azacitidine

Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 214 studies testing azacitidine in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

This phase II trial studies how well azacitidine and venetoclax work in treating patients with acute myeloid leukemia that is in remission. Drugs used in chemotherapy, such as azacitidine and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Read the detailed description

PRIMARY OBJECTIVES:

I. To assess relapse-free survival (RFS) of patients (pts) with acute myeloid leukemia (AML) treated with 5-azacytidine (azacitidine; AZA) combined with venetoclax (VEN) as maintenance therapy after achieving remission.

SECONDARY OBJECTIVES:

I. To assess modified RFS of pts with AML treated with 5-azacytidine combined with venetoclax as maintenance therapy.

II. To assess overall survival (OS) of pts with AML treated with 5-azacytidine combined with venetoclax as maintenance therapy.

III. To assess event-free survival (EFS) of pts with AML treated with 5-azacytidine combined with venetoclax as maintenance therapy.

IV. To assess the duration of remission (CRd) of pts with AML treated 5-azacytidine combined with venetoclax as maintenance therapy.

V. To assess toxicity and safety of 5-azacytidine combined with venetoclax as maintenance therapy in pts with AML.

VI. To assess the effects of 5-azacytidine combined with venetoclax on dynamics of minimal residual disease (MRD) and their relationship to outcomes.

OUTLINE:

Patients receive azacitidine subcutaneously (SC) or intravenously (IV) over 1 hour daily on days 1-5, and venetoclax orally (PO) daily on days 1-14. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days and then every 6-12 months thereafter.

03

Conditions studied

  • Acute Myeloid Leukemia in Remission
  • FLT3 Gene Mutation
  • Hematologic and Lymphocytic Disorder
  • Acute Myeloid Leukemia
  • Minimal Residual Disease Persistence
  • Therapy-Related Acute Myeloid Leukemia

Browse trials for

04

In context

Leukemia, Myeloid, Acute Reclassified

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

This study's enrollment of 36 is close to the median of 40 across 3,010 interventional studies indexed under Leukemia, Myeloid, Acute.

Browse Leukemia, Myeloid, Acute studies →

Lead sponsor

M.D. Anderson Cancer Center is the lead sponsor of 3,051 studies on the registry; 580 are open to participants now.

Of its 614 completed or terminated interventional studies of FDA-regulated products, 409 (67%) have results posted.

Compared within Leukemia, Myeloid, Acute, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hematologic Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged >/= 18 years AML who have achieved their FIRST CR or CRi and are not immediately candidates for stem cell transplant.
  2. Patients who have received intensive therapy (defined as receiving standard or higher dose cytarabine-based therapy) to achieve remission (CR/CRi) should have received remission induction therapy and at least 1 consolidation cycle. These patients are eligible as long as they are not greater than 2 months from their last consolidation therapy and will be enrolled in COHORT 1.
  3. Patients who have received lower intensity therapy (defined as receiving low-dose cytarabine (LDAC) or hypomethylating agent (HMA)-based therapy) to achieve remission should have received at least 2 cycles of lower intensity therapy between the time they have achieved CR/CRi and enrollment on this protocol. They will be treated on COHORT 2.
  4. For either subgroup (lower or higher intensity), patients who have measurable residual disease may be enrolled on their respective cohort at any time without maximum 'time from consolidation' requirement.
  5. performance status of \< or = 3
  6. Adequate organ function as follows:

    1. Serum total \< or = to 1.5 X the (ULN)
    2. Serum creatinine \< or = to 2.5 x ULN
  7. Adequate BM reserve:

    1. (ANC) > 0.5 x k/uL
    2. count > or = 30 x k/uL
  8. For females of childbearing age, they may participate if they:

    1. Have a negative serum or urine pregnancy test within 10 to 14 days of enrolling
    2. Agree to either abstinence or 2 effective methods (such as barrier methods or hormonal contraception) throughout the treatment period and up to 30 days after discontinuing treatment.
  9. For male patients with a female partner of childbearing age, they may participate if they agree to either abstinence or 2 effective contraceptive methods throughout the treatment period and up to 30 days after discontinuing treatment.
  10. Ability to understand and sign .

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of acute promyelocytic leukemia (APL), AML - M3 by FAB classification based on morphology, immunophenotype, molecular, or cytogenetic s studies.
  2. Diagnosis of AML associated t(15;17) or APL variant. Patients with t(9;22) are also ineligible unless they are unable or unwilling to receive therapy with a tyrosine kinase inhibitor.
  3. Uncontrolled intercurrent illness including, but not limited to active uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  4. Patients with active CNS (central nervous system) disease.
  5. Patients with documented to any components of the study program.
  6. Females who are pregnant or lactating or intending to become pregnant during the study.
  7. Patients with history of extramedullary AML, except for CNS involvement that is currently controlled, will not be eligible for enrollment.
  8. Patient should be removed from current trial if they wish to participate and get treatment on another trial.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Treatment (azacytidine, venetoclax)

    Patients receive azacitidine SC or IV over 1 hour daily on days 1-5, and venetoclax PO daily on days 1-14. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.

    Drug: Azacitidine · Drug: Venetoclax

Interventions

  • Given SC or IV

    Also known as: 5 AZC, 5-AC, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza

  • Given PO

    Also known as: ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto

07

What researchers measure

Primary outcomes

  1. Relapse-free survival (RFS)

    The study will be continuously monitored for the primary endpoint, RFS, using the method of Thall, Wooten, and Tannir (2005). Will also summarize the posterior distribution of lambda-E (i.e., median RFS) assuming posterior mean and 95% credible interval.

    Time frame: From date of complete remission (CR) or complete remission with incomplete count recovery (CRi), assessed for up to 10 years

Secondary outcomes

  1. Incidence of toxicity

    Toxicities are defined as any treatment -related clinically significant grade 3 or 4 non-hematologic adverse events occurred during cycles 1-2 of the trial. Will continuously monitor treatment-related toxicities using the Bayesian approach of Thall, Simon, Estey (1995).

    Time frame: Up to 10 years

  2. Modified RFS

    Distribution assessed using Kaplan-Meier method.

    Time frame: Time from enrollment on study until date of first objective documentation of relapse or death, assessed for up to 10 years

  3. Overall survival (OS)

    Distribution assessed using Kaplan-Meier method.

    Time frame: From the start of study treatment until date of death due to any cause, assessed for up to 10 years

  4. Event free survival (EFS)

    Distribution assessed using Kaplan-Meier method.

    Time frame: From the start of study treatment until date of first confirmed relapse, withdrawal from study due to adverse event, or death due to any cause, assessed for up to 10 years

  5. Complete remission duration (CRd)

    Distribution assessed using Kaplan-Meier method.

    Time frame: Time from CR or CRi until date of first objective documentation of confirmed relapse, assessed for up to 10 years

08

Study locations

1 site
  • M D Anderson Cancer Center
    Houston, Texas 77030, United States
09

References and documents

Publications

  • Bazinet A, Kantarjian H, Bataller A, Pemmaraju N, Borthakur G, Chien K, Alvarado Y, Bose P, Jabbour E, Yilmaz M, DiNardo C, Issa G, Montalban-Bravo G, Short N, Sasaki K, Bull-Linderman D, Daver N, Garcia-Manero G, Ravandi F, Kadia T. Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2024 Apr;11(4):e287-e298. doi: 10.1016/S2352-3026(24)00034-6. PubMed 38548404 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Sep 2019 to primary completion in Oct 2026, 84 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Oct 2030 → Oct 2026 and completion Oct 2030 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2019
First posted
Aug 20, 2019
StartActual
Sep 13, 2019
Primary completionActual
Oct 12, 2026was Oct 2030
CompletionActual
Oct 12, 2026was Oct 2030
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated \<75% participation
changed Oct 16, 2026
Primary completion
Oct 31, 2030→Oct 12, 2026 (actual)
Oct 16, 2026
Study completion
Oct 31, 2030→Oct 12, 2026 (actual)
Oct 16, 2026
Enrollment
50 (estimated)→36 (actual)
Oct 16, 2026
Documents
Oct 16, 2026
Show all 2 updates
  1. Oct 16, 2026
    Active, not recruiting→Terminated
    Why stopped \<75% participation
    Documents Informed consent form ↗ posted
    Primary completion Oct 31, 2030→Oct 12, 2026 (now actual)
    Study completion Oct 31, 2030→Oct 12, 2026 (now actual)
    Enrollment 50 (estimated)→36 (actual)
    + 1 other change: verification date
  2. Oct 5, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04062266
Responsible party
Sponsor
First posted
Aug 20, 2019
Start date
Sep 13, 2019
Primary completion
Oct 12, 2026
Completion
Oct 12, 2026
Last update
Oct 16, 2026

Study contacts

Tapan M Kadia
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Azacitidine · Venetoclax

Start the discussion